Fulgent Genetics Crescita futura
Criteri Future verificati 0/6
Si prevede che Fulgent Genetics aumenterà i profitti e i ricavi rispettivamente del 5% e 11.2% all'anno.
Informazioni chiave
5.0%
Tasso di crescita degli utili
n/a
Tasso di crescita dell'EPS
| Healthcare crescita degli utili | 18.4% |
| Tasso di crescita dei ricavi | 11.2% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 09 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento della narrazione • May 07
FLGT: Lower Multiple Assumptions Will Temper Long Term Upside Potential
Analysts have reduced the fair value estimate for Fulgent Genetics from $30.00 to $15.00 after lowering price targets, including cuts from $35.00 to $22.00 at UBS and by $15.00 at Piper Sandler, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. Analyst Commentary Recent research on Fulgent Genetics shows a clear tilt toward more conservative assumptions, with bearish analysts cutting price targets and resetting expectations on revenue growth, profit margins and valuation multiples such as future P/E levels.Seeking Alpha • Mar 12
Fulgent Genetics: A Major Market Misconception
Summary Fulgent Genetics' Q4 2025 earnings report caused a massive share price decline of roughly 40%. The sell off has exacerbated the market's misconception about FLGT that already existed before the earnings were released. An investor can use these new depressed prices to protect their downside while waiting patiently for a change in the company's fortunes to rerate shares dramatically to the upside. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Feb 19
FLGT: Higher Future P/E Assumptions Will Support Margin Driven Bullish Outlook
Analysts have lifted their price target on Fulgent Genetics by $2, reflecting updated assumptions around discount rates, profit margins, and future P/E expectations. Analyst Commentary Recent adjustments to the Fulgent Genetics price target reflect updated thinking on how the company might balance profitability, growth investments, and valuation multiples over time.Aggiornamento della narrazione • Feb 05
FLGT: Higher Future P/E Assumptions Will Support Long Term Upside
Analysts have lifted their fair value estimate for Fulgent Genetics from $21.00 to $30.00, citing updated assumptions about revenue growth, profit margins, and a higher future P/E multiple to support the new price target range. Analyst Commentary While the higher fair value estimate for Fulgent Genetics reflects more constructive assumptions, not every analyst is leaning in the same direction.Aggiornamento della narrazione • Jan 21
FLGT: Raised 2025 Guidance And Share Buybacks Will Support Bullish Outlook
Analysts have maintained their price target on Fulgent Genetics, citing only very small adjustments to the discount rate, long-term revenue growth, profit margin expectations, and future P/E assumptions, rather than any major change in their overall view of the company. What's in the News From July 1, 2025 to September 30, 2025, Fulgent Genetics reported no share repurchases under its existing program, with 0 shares bought for US$0 million in that period (Key Developments).Articolo di analisi • Jan 08
Health Check: How Prudently Does Fulgent Genetics (NASDAQ:FLGT) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Aggiornamento della narrazione • Jan 07
FLGT: Raised Guidance And Oncology Trial Progress Will Support Upside Potential
Analysts have maintained their price target for Fulgent Genetics at US$36.00, indicating relatively unchanged fair value and discount rate assumptions, along with slightly revised expectations for revenue growth, profit margin, and future P/E. What's in the News From July 1, 2025 to September 30, 2025, Fulgent Genetics reported no share repurchases under its existing program.Aggiornamento della narrazione • Dec 24
FLGT: Improved Profit Outlook And Pipeline Progress Will Support Upside Potential
Analysts have raised their price target on Fulgent Genetics from 30 dollars to 36 dollars, citing slightly improved long term profit margin expectations and a higher projected future price to earnings multiple, despite more conservative revenue growth assumptions and a modestly higher discount rate. What's in the News Raised full year 2025 guidance, now expecting approximately 325 million dollars in revenue and a GAAP loss of about 1.70 dollars per share, indicating increased confidence in the core business trajectory (Key Developments).Aggiornamento della narrazione • Dec 10
FLGT: Raised 2025 Guidance And Trial Progress Will Support Bullish Outlook
Analysts maintained their price target on Fulgent Genetics at approximately 33.67 dollars, citing largely unchanged expectations for revenue growth and valuation multiples, despite a modest reduction in projected profit margins. What's in the News Raised full year 2025 earnings guidance, now expecting approximately 325 million dollars in revenue and a GAAP loss of about 1.70 dollars per share, signaling improved visibility into core business trends (company guidance) Reported preliminary phase 2 clinical data for FID-007 in combination with cetuximab as a second line treatment for recurrent or metastatic head and neck squamous cell carcinoma, with results to be presented at the ESMO 2025 meeting in Berlin (company clinical update) Highlighted that FID-007 nanoparticles are smaller than solvent based PTX micelles, which enables deeper tumor penetration, slower clearance, and higher intratumoral accumulation due to the enhanced permeability and retention effect (company clinical update) Valuation Changes Fair Value Estimate remained unchanged at approximately 33.67 dollars per share, indicating no material shift in intrinsic value assumptions.Aggiornamento della narrazione • Nov 26
FLGT: Earnings Outlook And Clinical Data May Define Performance In 2025
Narrative Update on Fulgent Genetics Analyst Price Target Analysts have raised their price target for Fulgent Genetics from $27.00 to $33.67. This change is attributed to improved revenue growth and higher forecasted profit margins.Aggiornamento della narrazione • Nov 11
FLGT: Full-Year Guidance And Early Clinical Data Will Shape 2025 Outlook
Analysts have raised their price target for Fulgent Genetics from $25.33 to $27.00, citing slightly improved profit margin projections as well as updated market expectations. What's in the News Fulgent Genetics raised its earnings guidance for the full year 2025, expecting revenue of approximately $325 million and improving its EPS guidance to a GAAP loss of approximately $1.70 per share.Articolo di analisi • Nov 08
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price Is Out Of Tune With Revenues
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...Articolo di analisi • Aug 06
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Is On The Mark
NasdaqGM:FLGT 1 Year Share Price vs Fair Value Explore Fulgent Genetics's Fair Values from the Community and select...Aggiornamento della narrazione • Aug 06
Enhanced Whole Genome Sequencing Will Open New Global Markets
Fulgent Genetics’ fair value has been revised upward, primarily reflecting improved consensus revenue growth forecasts and a higher future P/E multiple, with the analyst price target rising from $22.67 to $25.33. What's in the News Fulgent Genetics expects core revenue of approximately $320 million for full year 2025.Articolo di analisi • May 09
Here's Why It's Unlikely That Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Will See A Pay Rise This Year
Key Insights Fulgent Genetics will host its Annual General Meeting on 15th of May Total pay for CEO Ming Hsieh includes...Articolo di analisi • May 05
Is Fulgent Genetics (NASDAQ:FLGT) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Nuova narrazione • Mar 28
Laboratory, Pathology And Therapeutics Will Expand Future Capabilities
Fulgent Genetics' laboratory services success and sales team's efficiency improvements should drive revenue growth and improve gross margins.Seeking Alpha • Mar 20
Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy
Summary CFO bought 1.5 million worth on March 5th, a Price/Book ratio of 0.43x and a Net Current Assets Value (NCAV) of 0.68x that day. Now it's trading at 0.47x Price/Book Value and 0.72x NCAV, showing a significant undervaluation. However, nothing is cheap for no reason; the company is not making money and won't for a while. The company has two promising drug candidates in its pipeline. Key trial results are expected at the ASCO meeting in May 2025. Current ownership is at 39%. That's quite a bit of skin in the game. Read the full article on Seeking AlphaArticolo di analisi • Jan 15
Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Dec 18
Fulgent Genetics: A Value Stock With Caveats (Rating Downgrade)
Summary Today, we revisit diagnostic testing concern Fulgent Genetics, Inc., which is currently navigating through the "COVID-19 cliff". Revenue growth should return in FY2025, and the company is sitting on a huge cash hoard on its balance sheet. An updated analysis around FLGT stock follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Sep 25
Fulgent Genetics: An NCAV Pick With Profit And Growth Potential
Summary Fulgent Genetics is transitioning from a diagnostic business to a fully integrated healthcare company, with a focus on oncology. Despite past reliance on COVID-19 test revenues, Fulgent's core business has grown significantly, with a strong balance sheet and zero debt. Trading below a conservative estimate of liquidation value, Fulgent presents a rare investment opportunity with potential for future growth and margin expansion as a bonus. Key risks include cash burn from drug development and potential for poor acquisitions, mitigated by CEO Ming Hsieh's significant equity stake. Read the full article on Seeking AlphaSeeking Alpha • Sep 09
Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst
Summary Fulgent Genetics’ core revenue grew just 3% in H1 2024, with full-year guidance of $280 million implying a step-up to 11% growth in H2 and 7% for FY 2024. Growth in precision diagnostics (+35% in H1 2024) and gross margin expansion (+650 basis points) were the two bright spots in first half results. Headwinds in anatomic pathology and BioPharma services will soften starting H2 2024, paving the way for core growth re-acceleration and operating margin improvements. At below $22, FLGT remains undervalued, not only trading well below my fair value of $34, but also 20% below its cash per share value of $27. Management’s M&A appetite remains a watch-out as CEO and biggest shareholder Ming Hsieh pursues his vision, which is unlikely to maximize short-term shareholder returns. Read the full article on Seeking AlphaArticolo di analisi • Jul 17
Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio
Fulgent Genetics, Inc.'s ( NASDAQ:FLGT ) price-to-sales (or "P/S") ratio of 2.3x may not look like an appealing...Seeking Alpha • Jun 06
Fulgent Genetics: Growth Is Returning
Summary Today, we put diagnostic company Fulgent Genetics, Inc. back in the spotlight as sales growth is returning after navigating a "Covid Cliff." While the company is still losing money, the stock is trading for less than the net cash on Fulgent's balance sheet. This should put a hard floor under the stock near current trading levels. An updated analysis around Fulgent Genetics follows in the paragraphs below. Read the full article on Seeking AlphaArticolo di analisi • May 10
Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package
Key Insights Fulgent Genetics will host its Annual General Meeting on 16th of May CEO Ming Hsieh's total compensation...Articolo di analisi • May 07
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
Investors in Fulgent Genetics, Inc. ( NASDAQ:FLGT ) had a good week, as its shares rose 4.4% to close at US$21.49...Articolo di analisi • Mar 01
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?
Key Insights Fulgent Genetics' estimated fair value is US$33.29 based on 2 Stage Free Cash Flow to Equity Fulgent...Seeking Alpha • Feb 21
Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Summary Fulgent Genetics spent the past 2 years digesting the Covid cliff, which wiped out 80% of its market capitalization since the 2021 peak. The company is about to hit an inflection point, as 2024 will be the year revenues return to growth while margins expand. The Fulgent Pharma business acquired at the end of 2022 will remain a drag near term but offers significant mid- to long-term upside potential. With a liquidation value of $27.50 and a fair value of $40 per share, FLGT provides a rare low-risk, high-reward opportunity to investors with a 3-5 years investment horizon. Read the full article on Seeking AlphaArticolo di analisi • Jan 17
Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...Articolo di analisi • Dec 14
Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Aug 09
Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • May 09
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
Fulgent Genetics, Inc. ( NASDAQ:FLGT ) just released its first-quarter report and things are looking bullish. The...Articolo di analisi • Apr 19
Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Articolo di analisi • Jan 15
Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Articolo di analisi • Dec 28
Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Nov 16
What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates
The analysts covering Fulgent Genetics, Inc. ( NASDAQ:FLGT ) delivered a dose of negativity to shareholders today, by...Articolo di analisi • Oct 27
Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Fulgent Genetics, Inc. ( NASDAQ:FLGT ), might not be a large cap stock, but it saw a double-digit share price rise of...Seeking Alpha • Oct 13
Wait For Fulgent Genetics To Grow Up
Summary We are bullish on the at-home testing healthcare market but bearish for retail value investors on Fulgent Genetics until growth and momentum improve. They reported revenue growth and profits, hold a lot of cash, but face a year of possible slowing revenue and significantly lower EPS. Competition is stiff in this market and discretionary consumer spending may slow with the looming recession. Demand for genetic testing is growing fast and furious now that respiratory and COVID-19 testing is slowing. We are bullish on the at-home testing healthcare market but bearish for retail value investors on Fulgent Genetics, Inc. (FLGT). We do not forecast bright revenue and earnings per share. This stock faces several headwinds. It is not a potentially valuable opportunity, in our opinion, worth the lack of dividend and risk after one year of surprising growth. Testing Market Fulgent Genetics might prove to be a long-term investment opportunity. Perhaps a larger firm sees Fulgent as an M&A opportunity wanting their proprietary scientific genetic testing advances? Growth potential seems limited by inadequate marketing to consumers. Seeking Alpha gives Fulgent relatively low grades for momentum and revisions. The past year was profitable, but we do not expect future revenue and earnings per share to repeat FY '21. The shares of other testing companies about which we wrote for Seeking Alpha, Trinity Biotech plc (TRIB), and EXACT Sciences Corp. (EXAS), are slumping, too. Ratings and Grades (seekingalpha.com) The genetic testing industry burgeoned when manufacturers produced and marketed rapid Medical Testing and Diagnostic Kits, or MTDKs, for at-home (and in medical offices) use. 2019 was one of its best years. Individuals and medical personnel use MTDK tools to swab or take blood and DNA samples at home or in the office. They mail the samples to central labs. Results run through data banks. The data identify genetic links to unknown family members and for diseases, including malaria, HIV, cancer, and more. EXAS shares doubled in 18 months, hitting ~$95 in 2019. The shares skyrocketed to $154 in 2021. Headwinds to Stock Growth The market is highly competitive and dominated by pharma and biotech behemoths. Three headwinds slowed the rapid MTDK industry growth. The first is the shift in biotech business plans; stakeholders favor fast growth over building customer bases and long-term profitability. M&As by Exact Sciences contributed to a share price collapse; they tumbled down -65.6% to $32.16 near the time of this article. Second, the pandemic brought a plethora of kits to market from heretofore unknown manufacturers. COVID test kits from China and elsewhere flooded the marketplace; many proved to produce unreliable results, increasing user skepticism about the disease and the kits. Lesser-known manufacturers and sellers offered them at giveaway prices. For example, Lloyds Pharmacy took to the Internet to advertise at-home kits for less than $2 each. The third factor slowing the growth of the more costly but scientific-based testing industry was the rapid spread of the coronavirus. Labs focused on the disease that was killing millions; lab workers could not travel to work and they themselves got sick, and a lab worker shortage grew exponentially as the disease spread. Many never returned to work. Supply chain issues arose. Governments diverted resources and motivated manufacturers to develop C-19 rapid test kits at the expense of genetic testing kits and lab time for other diseases. The Company The genetic testing market is growing again at a CAGR of +10% annually. Genetic testing is growing concomitant with increasing attention and services to better healthcare and middle-class expansion. It's projected that the genetic testing market will top $36B by 2030. The primary markets for rapid MTDKs are: · Predictive and pre-symptomatic testing · Carrier testing · Prenatal and newborn testing · Diagnostic testing · Pharmacogenomic testing · Cytogenetic, biochemical, and molecular testing · Cancer diagnosis, genetic disease diagnosis, cardiovascular diagnosis Testing by Type (alliedmarketresearch.com) Testing Market (alliedmarketresearch.com) Fulgent is a recent entrant into the genetic testing marketplace. Founded in 2011, Fulgent is now a full-service genomic testing company built around a foundational technology platform. Fulgent focuses on testing in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. They have 7 certified labs in the U.S. and a slew of accreditations. Its most noteworthy accomplishment is that Fulgent was the first clinical lab offering copy number variation detection using NGS technology. Valuation Shares are down over 52% in the past 52 weeks despite having closed 2021 at around $100. From the peak, the share price steadily descended to about $36 in October '22. Short interest rose to 6.31%, which we find uncomfortable. Seeking Alpha authors recommend holding shares. SA's Quant Rating calls for holding the stock. The stock status has been on hold for ten months, since early '22. There are no expected events sparking much movement in the share price. Even the Beta rating is below market volatility, standing at 0.88. We think a fair average price target for Fulgent Genetics' shares over the next 12 months is a high of $41.00 if revenue and earnings beat forecasts. The company will likely continue to be profitable, but the looming recession might limit consumer healthcare-testing spending. Fulgent debt is a mere ~$21M, while equity tops $81M. So far, the company reports strong operating cash flow and earns more interest than it pays. Cash and investments are $515.4M, receivables are $137.5M, and other assets +$808M. But the company does not pay any dividends, so holding for the long term in this market environment may cost money to investors. Valuations from others range from $67 to $146, but we discount them. The company is young and historical multiples, past returns, and future growth estimates are based on uninspired guesswork in our opinion. Revenue Chart (seekingalpha.com) Concomitantly, corporate insiders have been unloading shares for a while. They sold shares worth about $240K in the last three months; they sold far many more shares over the past 11 months than corporate insiders bought. Hedge funds lowered their holdings by 1.4K shares last quarter. 24 funds held Fulgent stock at the end of last year, but only 18 funds hold shares today. The consensus is that 2021 was a banner revenue year ($992.58M).Articolo di analisi • Sep 19
We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...Articolo di analisi • Sep 05
Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Seeking Alpha • Jul 26
Fulgent Genetics: Poised To Survive Its Post-Covid Hangover
Today, we take a deeper look at Fulgent Genetics, which has benefitted greatly from an explosion of Covid-19 testing revenue. The stock has sold off as fears around the coronavirus have ebbed. However, the company has a huge cash hoard to build up the other parts of its product portfolio. An investment analysis follows in the paragraphs below. "I used to advertise my loyalty and I don't believe there is a single person I loved that I didn't eventually betray." - Albert Camus, The Fall Today, we are putting Fulgent Genetics (FLGT) in the spotlight. The company has been a huge beneficiary of the pandemic. Covid-19 testing revenues powered a thirteen-fold increase in overall sales in the company's 4Q2020 earnings report as a good example of the magnitude of the benefit. Subsequently, the stock rocketed up from $10 a share in March 2020 to $160 in January 2021. Seeking Alpha However, as pandemic fears have ebbed considerably lately, the stock has sold off some 45% since late last year and is down nearly two-thirds from its all-time highs. Time to accumulate some shares in this diagnostic testing concern? An analysis follows below. Company Overview: Fulgent Genetics provides numerous tests and testing services and is based just outside of Los Angeles. Its product portfolio includes Covid-19, molecular diagnostic, and genetic testing. As noted above, the majority of revenues are coming from Covid-19 testing, its specialized oncology and other tests are what the company calls its 'core' revenue-generating part of the company. May Company Presentation The stock sells for around $58.00 a share and sports an approximate market capitalization of $1.75 billion. May Company Presentation First Quarter Results: On May 3rd, Fulgent posted first quarter numbers. The company had non-GAAP earnings of $5.12 a share on revenues of $320 million. Both top and bottom line results easily beat expectations. GAAP profits per share were $4.83. Revenue was down from nearly $360 million in the same period a year ago, solely as a result of a decrease from Covid testing. 'Core' revenue was up 59% to $25.1 million. Management raised its full-year guidance to $660 million worth of sales but took down full year non-GAAP income a buck to $6.00 a share. May Company Presentation Shortly after the quarter closed, Fulgent acquired Inform Diagnostics, a national independent pathology laboratory based in Irving, Texas, for $170 million. May Company Presentation Fulgent Genetics also purchased CSI Laboratories in 2021. May Company Presentation This triggered leadership to move up their estimate of 'core' revenue for FY2022 to approximately $175 million from $120 million previously. At its earnings call in early May, the leadership moved up its estimate for core revenue further to $180 million. May Company Presentation Analyst Commentary & Balance Sheet: Despite a decent-sized market cap, Fulgent Genetics gets short shrift from Wall Street. On January 25th, maintained its Buy rating on FLGT but lowered its price target from $141 to $125 a share. In late May, Piper Sandler reissued its Buy rating after meeting with management. Piper's analyst stated that he was: Impressed with the company's core growth, potential in its COVID business, and "optionality" with its $1.1B in cash. The analyst believes Fulgent is setting itself up to add growth via acquisitions, particularly as other labs struggle with cash management."Articolo di analisi • Jul 21
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
With a price-to-earnings (or "P/E") ratio of 4x Fulgent Genetics, Inc. ( NASDAQ:FLGT ) may be sending very bullish...Articolo di analisi • Jun 04
Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 435 | -69 | N/A | N/A | 1 |
| 12/31/2027 | 402 | -73 | N/A | N/A | 1 |
| 12/31/2026 | 352 | -90 | N/A | N/A | 1 |
| 3/31/2026 | 320 | -74 | -113 | -90 | N/A |
| 12/31/2025 | 323 | -61 | -124 | -102 | N/A |
| 9/30/2025 | 316 | -43 | -20 | 2 | N/A |
| 6/30/2025 | 303 | -51 | -60 | -25 | N/A |
| 3/31/2025 | 292 | -41 | -32 | 9 | N/A |
| 12/31/2024 | 283 | -43 | -19 | 21 | N/A |
| 9/30/2024 | 278 | -165 | -29 | 11 | N/A |
| 6/30/2024 | 291 | -163 | 12 | 37 | N/A |
| 3/31/2024 | 288 | -166 | 18 | 42 | N/A |
| 12/31/2023 | 289 | -168 | 5 | 27 | N/A |
| 9/30/2023 | 286 | -64 | 21 | 45 | N/A |
| 6/30/2023 | 307 | -49 | 31 | 56 | N/A |
| 3/31/2023 | 365 | -26 | 42 | 57 | N/A |
| 12/31/2022 | 619 | 143 | 235 | 254 | N/A |
| 9/30/2022 | 803 | 272 | 277 | 297 | N/A |
| 6/30/2022 | 925 | 392 | 411 | 429 | N/A |
| 3/31/2022 | 953 | 461 | 476 | 494 | N/A |
| 12/31/2021 | 993 | 507 | 515 | 539 | N/A |
| 9/30/2021 | 1,036 | 569 | 554 | 596 | N/A |
| 6/30/2021 | 910 | 493 | 405 | 453 | N/A |
| 3/31/2021 | 773 | 417 | 327 | 372 | N/A |
| 12/31/2020 | 422 | 214 | 105 | 141 | N/A |
| 9/30/2020 | 135 | 48 | -6 | 6 | N/A |
| 6/30/2020 | 44 | 3 | -1 | 1 | N/A |
| 3/31/2020 | 35 | 0 | 4 | 6 | N/A |
| 12/31/2019 | 33 | 0 | N/A | 6 | N/A |
| 9/30/2019 | 30 | -2 | N/A | 6 | N/A |
| 6/30/2019 | 25 | -4 | N/A | 2 | N/A |
| 3/31/2019 | 22 | -6 | N/A | 2 | N/A |
| 12/31/2018 | 21 | -6 | N/A | -1 | N/A |
| 9/30/2018 | 20 | -5 | N/A | -3 | N/A |
| 6/30/2018 | 19 | -6 | N/A | -2 | N/A |
| 3/31/2018 | 18 | -5 | N/A | -1 | N/A |
| 12/31/2017 | 19 | -3 | N/A | 1 | N/A |
| 9/30/2017 | 20 | 0 | N/A | 4 | N/A |
| 6/30/2017 | 21 | -5 | N/A | 4 | N/A |
| 3/31/2017 | 20 | -13 | N/A | 5 | N/A |
| 12/31/2016 | 18 | -14 | N/A | 4 | N/A |
| 9/30/2016 | 15 | -22 | N/A | 3 | N/A |
| 6/30/2016 | 13 | -15 | N/A | 2 | N/A |
| 3/31/2016 | 11 | -6 | N/A | 0 | N/A |
| 12/31/2015 | 10 | -5 | N/A | -1 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che FLGT rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che FLGT rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che FLGT rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di FLGT ( 11.2% all'anno) crescerà più lentamente rispetto al mercato US ( 11.7% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di FLGT ( 11.2% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di FLGT è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/22 18:55 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Fulgent Genetics, Inc. è coperta da 5 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Karen Koski | BTIG |
| Andrew Cooper | CGS International |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |